SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual ...

Scienture Holdings, Inc.: SCIENTURE Provides Commercial Update on ARBLI, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Company highlights accelerating access and revenue growth for ARBLI and confirms REZENOPY launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Ou ...